Touyun Biotech Group 미래 성장

Future 기준 확인 0/6

현재 Touyun Biotech Group 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Packaging 수익 성장	30.4%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

업데이트 없음

Recent updates

Revenues Not Telling The Story For Touyun Biotech Group Limited (HKG:1332) After Shares Rise 29%

Sep 15

Touyun Biotech Group Limited's (HKG:1332) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jul 17

Risks Still Elevated At These Prices As Touyun Biotech Group Limited (HKG:1332) Shares Dive 28%

Apr 22

Would Touyun Biotech Group (HKG:1332) Be Better Off With Less Debt?

Apr 08

What Touyun Biotech Group Limited's (HKG:1332) 46% Share Price Gain Is Not Telling You

Feb 07

Some Touyun Biotech Group Limited (HKG:1332) Shareholders Look For Exit As Shares Take 42% Pounding

Dec 18

Touyun Biotech Group (HKG:1332) Is Carrying A Fair Bit Of Debt

Sep 19

Risks To Shareholder Returns Are Elevated At These Prices For Touyun Biotech Group Limited (HKG:1332)

Jul 28

Could The China Touyun Tech Group Limited (HKG:1332) Ownership Structure Tell Us Something Useful?

Mar 12

If You Had Bought China Touyun Tech Group (HKG:1332) Shares A Year Ago You'd Have Earned 380% Returns

Jan 15

The Executive Chairman of China Touyun Tech Group Limited (HKG:1332), Liang Wang, Just Bought 8.8% More Shares

Jan 15

How Much Of China Touyun Tech Group Limited (HKG:1332) Do Insiders Own?

Dec 11

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Touyun Biotech Group 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

SEHK:1332 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (HKD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2024	170	-233	-62	-45	N/A
3/31/2024	184	-251	-38	-21	N/A
12/31/2023	199	-269	-13	4	N/A
9/30/2023	226	-231	12	26	N/A
6/30/2023	253	-194	37	49	N/A
3/31/2023	284	-196	-1	11	N/A
12/31/2022	316	-198	-39	-26	N/A
9/30/2022	314	-149	-40	5	N/A
6/30/2022	313	-100	-40	36	N/A
3/31/2022	298	-86	-129	-9	N/A
12/31/2021	284	-73	-217	-54	N/A
9/30/2021	268	-110	-307	-128	N/A
6/30/2021	252	-148	-398	-203	N/A
3/31/2021	229	-158	-269	-109	N/A
12/31/2020	207	-169	-141	-15	N/A
9/30/2020	230	-190	-125	-51	N/A
6/30/2020	252	-212	-109	-87	N/A
3/31/2020	298	-206	-161	-146	N/A
12/31/2019	343	-201	-213	-205	N/A
9/30/2019	357	-221	-165	-164	N/A
6/30/2019	371	-242	-117	-122	N/A
3/31/2019	360	-248	-135	-120	N/A
12/31/2018	349	-254	-153	-117	N/A
9/30/2018	364	-245	-161	-94	N/A
6/30/2018	378	-236	-168	-71	N/A
3/31/2018	348	-240	N/A	-56	N/A
12/31/2017	318	-245	N/A	-41	N/A
6/30/2017	163	-917	N/A	-126	N/A
3/31/2017	62	-1,006	N/A	50	N/A
12/31/2016	-38	-1,095	N/A	226	N/A
6/30/2016	58	-357	N/A	-300	N/A
3/31/2016	172	-51	N/A	-380	N/A
12/31/2015	286	255	N/A	-459	N/A
9/30/2015	309	302	N/A	N/A	N/A
6/30/2015	332	349	N/A	173	N/A
3/31/2015	365	180	N/A	101	N/A
12/31/2014	397	10	N/A	28	N/A
9/30/2014	405	10	N/A	15	N/A
6/30/2014	414	10	N/A	2	N/A
3/31/2014	425	11	N/A	8	N/A
12/31/2013	436	13	N/A	14	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 1332 의 예상 수익 증가율이 절약률( 2.3% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: 1332 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 1332 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: 1332 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 1332 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 1332 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Touyun Biotech Group 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Recent updates

First half 2024 earnings released: HK$0.017 loss per share (vs HK$0.03 loss in 1H 2023)

Revenues Not Telling The Story For Touyun Biotech Group Limited (HKG:1332) After Shares Rise 29%

Non-Executive Director recently sold HK$111k worth of stock

First half 2024 earnings released: HK$0.017 loss per share (vs HK$0.03 loss in 1H 2023)

New major risk - Negative shareholders equity

Touyun Biotech Group Limited to Report First Half, 2024 Results on Aug 23, 2024

Touyun Biotech Group Limited's (HKG:1332) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Risks Still Elevated At These Prices As Touyun Biotech Group Limited (HKG:1332) Shares Dive 28%

Would Touyun Biotech Group (HKG:1332) Be Better Off With Less Debt?

Full year 2023 earnings released: HK$0.096 loss per share (vs HK$0.071 loss in FY 2022)

Touyun Biotech Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

What Touyun Biotech Group Limited's (HKG:1332) 46% Share Price Gain Is Not Telling You

New major risk - Share price stability

Non-Executive Director recently sold HK$173k worth of stock

Some Touyun Biotech Group Limited (HKG:1332) Shareholders Look For Exit As Shares Take 42% Pounding

New minor risk - Market cap size

First half 2023 earnings released: HK$0.03 loss per share (vs HK$0.031 loss in 1H 2022)

Touyun Biotech Group (HKG:1332) Is Carrying A Fair Bit Of Debt

First half 2023 earnings released: HK$0.03 loss per share (vs HK$0.031 loss in 1H 2022)

Touyun Biotech Group Limited to Report First Half, 2023 Results on Aug 25, 2023

Risks To Shareholder Returns Are Elevated At These Prices For Touyun Biotech Group Limited (HKG:1332)

New major risk - Share price stability

Non-Executive Director recently sold HK$110k worth of stock

Full year 2022 earnings released

Less than half of directors are independent

Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt

First half 2022 earnings released: HK$0.031 loss per share (vs HK$0.022 loss in 1H 2021)

Touyun Biotech Group Limited Announces Company Secretary Changes, Effective August 02, 2022

Touyun Biotech Group (HKG:1332) Is Making Moderate Use Of Debt

Less than half of directors are independent

Full year 2021 earnings released: EPS: HK$0.026 (vs HK$0.063 loss in FY 2020)

Touyun Biotech Group Limited to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Touyun Biotech Group Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt

First half 2021 earnings released: HK$0.022 loss per share (vs HK$0.032 loss in 1H 2020)

Full year 2020 earnings released: HK$0.063 loss per share (vs HK$0.082 loss in FY 2019)

Full year 2020 earnings released: EPS HK$0.063 (vs HK$0.082 loss in FY 2019)

China Touyun Tech Group Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

Could The China Touyun Tech Group Limited (HKG:1332) Ownership Structure Tell Us Something Useful?

If You Had Bought China Touyun Tech Group (HKG:1332) Shares A Year Ago You'd Have Earned 380% Returns

The Executive Chairman of China Touyun Tech Group Limited (HKG:1332), Liang Wang, Just Bought 8.8% More Shares

New 90-day high: HK$0.80

New 90-day high: HK$0.58

How Much Of China Touyun Tech Group Limited (HKG:1332) Do Insiders Own?

China Touyun Tech Group Limited Announces Changes to Its Board

New 90-day high: HK$0.50

New 90-day low: HK$0.29

First half earnings released

First half earnings released

China Touyun Tech Group Limited to Report First Half, 2020 Results on Aug 26, 2020

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견